Nanobiotix's IPO Triggers Calls In Europe For More "Citizen Funding"
This article was originally published in The Pink Sheet Daily
Executive Summary
Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.